12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Other News

Roche infectious news

India's Intellectual Property Appellate Board (IPAB) revoked a patent covering Roche's HCV drug Pegasys peginterferon alfa-2a on the grounds of obviousness. The patent covers the use of pegylation to improve the efficacy of interferon to treat HCV infection. In its ruling, the IPAB said prior art covering branched, pegylated...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >